These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34707096)

  • 1. In-depth proteomic profiling captures subtype-specific features of craniopharyngiomas.
    Kim JH; Kim H; Dan K; Kim SI; Park SH; Han D; Kim YH
    Sci Rep; 2021 Oct; 11(1):21206. PubMed ID: 34707096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
    Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
    Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
    Esheba GE; Hassan AA
    J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the shared pathways and common biomarker in adamantinomatous craniopharyngioma and type 2 diabetes using integrated bioinformatics analysis.
    Han Y; Wang Y; Li S; Sato K; Yamagishi S
    PLoS One; 2024; 19(6):e0304404. PubMed ID: 38848397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
    Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
    Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice.
    Apps JR; Martinez-Barbera JP
    Neurosurg Focus; 2016 Dec; 41(6):E4. PubMed ID: 27903120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent adamantinomatous craniopharyngiomas show MAPK pathway activation, clonal evolution and rare TP53-loss-mediated malignant progression.
    Apps JR; Gonzalez-Meljem JM; Guiho R; Pickles JC; Prince E; Schwalbe E; Joshi N; Stone TJ; Ogunbiyi O; Chalker J; Bassey A; Otto G; Davies R; Hughes D; Brandner S; Tan E; Lee V; Hayhurst C; Kline C; Castellano S; Hankinson T; Deutschbein T; Jacques TS; Martinez-Barbera JP
    Acta Neuropathol Commun; 2024 Aug; 12(1):127. PubMed ID: 39127699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular pathogenesis of craniopharyngiomas.
    Campanini ML; Almeida JP; Martins CS; de Castro M
    Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Simvastatin on Inflammatory Response and Biological Behaviour of Adamantinomatous Craniopharyngioma.
    Li W; Zhang Y; Zhuang Y; Chen R; Xiong Z; Li K; Liu F; Xu H; Li D; Peng J
    Neuroendocrinology; 2024; 114(10):934-949. PubMed ID: 38964285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative analyses identify HIF-1α as a potential protective role with immune cell infiltration in adamantinomatous craniopharyngioma.
    Gao Q; Luo J; Pan J; Zhang L; Song D; Zhang M; Xu D; Guo F
    Front Immunol; 2022; 13():949509. PubMed ID: 36091021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
    Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
    J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth patterns of craniopharyngiomas: clinical analysis of 226 patients.
    Pan J; Qi S; Liu Y; Lu Y; Peng J; Zhang X; Xu Y; Huang GL; Fan J
    J Neurosurg Pediatr; 2016 Apr; 17(4):418-33. PubMed ID: 26636252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
    Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
    Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis.
    Prince EW; Apps JR; Jeang J; Chee K; Medlin S; Jackson EM; Dudley R; Limbrick D; Naftel R; Johnston J; Feldstein N; Prolo LM; Ginn K; Niazi T; Smith A; Kilburn L; Chern J; Leonard J; Lam S; Hersh DS; Gonzalez-Meljem JM; Amani V; Donson AM; Mitra SS; Bandopadhayay P; Martinez-Barbera JP; Hankinson TC
    Neuro Oncol; 2024 Jun; 26(6):1109-1123. PubMed ID: 38334125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpCAM (CD326) is differentially expressed in craniopharyngioma subtypes and Rathke's cleft cysts.
    Thimsen V; Hölsken A; Buchfelder M; Flitsch J; Fahlbusch R; Stefanits H; Losa M; Jones DT; Buslei R
    Sci Rep; 2016 Jul; 6():29731. PubMed ID: 27431859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
    Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
    Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
    J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
    Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
    Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Odontogenic classification of craniopharyngiomas: a clinicopathological study of 54 cases.
    Paulus W; Stöckel C; Krauss J; Sörensen N; Roggendorf W
    Histopathology; 1997 Feb; 30(2):172-6. PubMed ID: 9067743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the calcification of adamantinomatous craniopharyngioma resemble the calcium deposition of osteogenesis/odontogenesis?
    Song-Tao Q; Xiao-Rong Y; Jun P; Yong-Jian D; Jin L; Guang-Long H; Yun-Tao L; Jian R; Xiang-Zhao L; Jia-Ming X
    Histopathology; 2014 Feb; 64(3):336-47. PubMed ID: 24387671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.